glp-1-directed nmda receptor antagonism for obesity treatment Schematic illustration of monoagonists, dual agonists and triple GLP-1 Agonists for Obesity Treatment:
Description
The average body weight loss with tirzepatide is 21% after 18 months, compared to 3% with placebo
The FDA has only approved Ozempic for those who have diabetes and kidney disease
But some people experience appetite suppression so aggressively that they struggle to eat enough to meet basic nutritional needs
Stay consistent with your dosing day and follow your nutrition plan
The question is no longer whether they protect the heart
